氨基酸受体表型的结构基础
Jianjun Cao1,2, Matthew J Belousoff1,2, Yi-Lynn Liang1
1Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia.
概括
氨酸受体 (AMYR) 和氨酸受体 (CTR) 的结合方式不同. 了解这些独特的结合机制对于开发针对AMYR的新型肥胖治疗至关重要.
科学领域:
- 生物化学
- 结构生物学
- 药理学
背景情况:
- 氨酸受体 (AMYR) 是氨酸受体 (CTR) 和受体活性修饰蛋白 (RAMP) 的异构体.
- AMYR和CTR是肥胖治疗的目标,但它们的结和选择性的分子基础仍然不清楚.
- 了解这些相互作用对于合理的药物设计至关重要.
研究的目的:
- 确定与氨酸和CT基结合的活性AMYR的结构和动态.
- 阐明 AMYR 和 CTR 的结和选择性的分子机制.
- 为开发针对AMYR的新疗法提供信息.
主要方法:
- 确定了与氨酸复合的活性AMYR的冷电子显微镜结构.
- 用鱼CT (sCT) 和人类CT (hCT) 确定AMY1R和AMY2R的结构.
- 确定了与氨酸,sCT和hCT复合的CTR结构.
主要成果:
- 氨酸结合的AMYR复合物采用了保留的形状,具有RAMP受约束的旁路图案.
- 与氨酸结合的复合物相比,CT结合的AMYR复合物呈现出不同的结构.
- 与CT结合的AMYR结构与CT结合的CTR结构重叠,表明共享的结合元素.
结论:
- 基于CT的的AMYR激活与氨酸的激活有机理上的不同.
- 发现的结构差异为AMYR和CTR选择性提供了洞察力.
- 这些发现对治疗肥胖和其他代谢障碍的AMYR激活剂有重要意义.
相关概念视频
Insulin: The Receptor and Signaling Pathways
1.6K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.6K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.5K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.5K
Amyloid Fibrils
10.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.2K
The Two-State Receptor Model
2.5K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.5K
Insulin: Biosynthesis, Chemistry, and Preparation
605
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
605
Glucagon-like Receptor Agonists
452
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
452


